Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab-IRDye800 and 89Zr-Panitumumab Imaging in Head and Neck Cancer
NCT03733210Phase 1Completed
- Sponsor
- Andrei Iagaru
- Start
- Jan 2019
- Primary completion
- Dec 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of panitumumab and zirconium Zr 89 panitumumab in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by Andrei Iagaru. Primary endpoint: Sensitivity and Specificity of 89Zr-panitumumab for the detection of tumor-involved regional lymph nodes up to 5 days. Started Jan 2019; status: completed.
02
Drugs
panitumumabzirconium Zr 89 panitumumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03733210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03733210.